指南与共识医院感染防控

ESCMID免疫功能受损宿主感染研究组(ESGICH)关于靶向与生物治疗安全性的共识文件:感染病学视角(靶向淋巴或髓系细胞表面抗原的药物[II]:CD22、CD30、CD33、CD38、CD40、SLAMF-7与CCR4)

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4).
指南 / 共识 · Clin Microbiol Infect · 2018-03-20

本综述为ESGICH共识文件的一部分,从感染病学角度评估靶向CD22、CD30、CD33、CD38、CD40、SLAMF-7和CCR4药物的感染风险谱,并给出预防建议。CD30靶向药推荐抗肺孢子菌预防和CMV监测;CD38靶向药增加VZV感染风险;CD40靶向药相关机会性感染需预防策略;CCR4靶向药推荐抗肺孢子菌和抗疱疹病毒预防及慢性HBV筛查。

要点

  • CD30靶向药(维布妥昔单抗)推荐抗肺孢子菌预防和CMV监测。
  • CD38靶向药(达雷妥尤单抗)增加水痘-带状疱疹病毒感染风险。
  • CCR4靶向药(莫格利珠单抗)推荐抗肺孢子菌和抗疱疹病毒预防及慢性HBV筛查。

核心结论

  • 应制定具体管理策略以降低所评估药物相关感染并发症的风险和/或严重程度。

研究设计与样本

  • ESCMID免疫功能受损宿主感染研究组(ESGICH)共识文件,采用计算机检索MEDLINE(MeSH词涉及每种药物或治疗家族)的综述。

主要发现

  • 接受CD22靶向药(奥加伊妥珠单抗)患者的感染风险和谱与抗CD20抗体相似。
  • CD33靶向药(吉妥珠单抗奥唑米星)所致风险因数据稀缺无法评估。
  • 接受CD38靶向药(达雷妥尤单抗)患者面临水痘-带状疱疹病毒感染风险增加。
  • CD40靶向药(卢卡妥木单抗或达西妥木单抗)治疗与类似高IgM综合征的机会性感染相关。
  • SLAMF-7(CD319)靶向药(埃罗妥珠单抗)诱导淋巴细胞减少并增加感染风险(尤其VZV)。

关键数值与推荐

  • CD30靶向药(维布妥昔单抗)推荐抗肺孢子菌预防和CMV感染监测。
  • CD40靶向药需预防策略(包括抗肺孢子菌预防和CMV感染抢先治疗)。
  • CCR4靶向药(莫格利珠单抗)推荐抗肺孢子菌和抗疱疹病毒预防及慢性HBV感染筛查。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • CD33靶向药(吉妥珠单抗奥唑米星)所致风险因数据稀缺无法评估。
  • CCR4靶向药(莫格利珠单抗)对感染易感性的影响难以与基础疾病和合并治疗的作用区分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. AIMS: To review, from an Infectious Diseases perspective, the safety profile of agents targeting CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4 and to suggest preventive recommendations. SOURCES: Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family. CONTENT: The risk and spectrum of infections in patients receiving CD22-targeted agents (i.e. inotuzumab ozogamicin) are similar to those observed with anti-CD20 antibodies. Anti-Pneumocystis prophylaxis and monitoring for cytomegalovirus (CMV) infection is recommended for patients receiving CD30-targeted agents (brentuximab vedotin). Due to the scarcity of data, the risk posed by CD33-targeted agents (gemtuzumab ozogamicin) cannot be assessed. Patients receiving CD38-targeted agents (i.e. daratumumab) face an increased risk of varicella-zoster virus (VZV) infection. Therapy with CD40-targeted agents (lucatumumab or dacetuzumab) is associated with opportunistic infections similar to those observed in hyper-IgM syndrome, and prevention strategies (including anti-Pneumocystis prophylaxis and pre-emptive therapy for CMV infection) are warranted. SLAMF-7 (CD319)-targeted agents (elotuzumab) induce lymphopenia and increase the risk of infection (particularly due to VZV). The impact of CCR4-targeted agents (mogamulizumab) on infection susceptibility is difficult to distinguish from the effect of underlying diseases and concomitant therapies. However, anti-Pneumocystis and anti-herpesvirus prophylaxis and screening for chronic hepatitis B virus (HBV) infection are recommended. IMPLICATIONS: Specific management strategies should be put in place to reduce the risk and/or the severity of infectious complications associated to the reviewed agents.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Drgona L, Gudiol C, Lanini S, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect. 2018. PMID: 29572070. doi:10.1016/j.cmi.2018.03.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。